LIVIVO - Search results -

Search results

Result 1 - 10 of total 11

Search options

Article ; Online: Could the new coronavirus have infected humans prior November 2019?

Tichopád, Aleš / Pecen, Ladislav / Sedlák, Vratislav

2021 Volume 16, Issue 8, Page(s) e0248255

Abstract: The pandemic caused by the SARS-CoV-2 virus is believed to originate in China from where it spread to other parts of the world. The first cluster of diseased individuals was reported in China as early as in December 2019. It has also been well ... ...

Abstract	The pandemic caused by the SARS-CoV-2 virus is believed to originate in China from where it spread to other parts of the world. The first cluster of diseased individuals was reported in China as early as in December 2019. It has also been well established that the virus stroke Italy later in January or in February 2020, hence distinctly after the outbreak in China. The work by Apolone et al. published in the Italian Medical Journal in November 2020 and retracted upon expression of concern on 22 March 2021, however propose that the virus could have stroke people already in September 2019, possibly following even earlier outbreak in China. By fitting an early part of the epidemic curve with the exponential and extrapolating it backwards, we could estimate the day-zero of the epidemic and calculated its confidence intervals in Italy and China. We also calculated how probable it is that Italy encountered the virus prior 1 January 2020. We determined an early portion of the epidemic curve representing unhindered exponential growth which fit the exponential model with high determination >0.97 in both countries. We conservatively suggest that the day-zero in China and Italy was 8 December 2019 (95% CI: 3 Dec., 20 Dec.) and 22 January 2020 (95% CI: 16 Jan., 29 Jan.), respectively. Given the uncertainty of the very early data in China and adjusting hence our model to fit the exponentially behaved data only, we can even admit that the pandemic originated through November 2019 (95% CI: 31 Oct., 22 Dec.). With high confidence (p <0.01) China encountered the virus prior Italy. We generally view any pre-pandemic presence of the virus in humans before November 2019 as very unlikely. The later established dynamics of the epidemics data suggests that the country of the origin was China.
MeSH term(s)	COVID-19/epidemiology ; COVID-19/transmission ; China/epidemiology ; Humans ; Italy/epidemiology ; Models, Biological ; Pandemics ; SARS-CoV-2
Language	English
Publishing date	2021-08-19
Publishing country	United States
Document type	Journal Article
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0248255
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Adherence to application technique of inhaled corticosteroid in patients with asthma and COVID-19 improves outcomes.

Tichopád, Aleš / Žigmond, Jan / Jeseňák, Miloš / Solovič, Ivan / Breciková, Katarína / Rybář, Marian / Rožánek, Martin / Sedlák, Vratislav

BMJ open respiratory research

2024 Volume 11, Issue 1

Abstract: Background: Inhaled corticosteroids have been widely reported as a preventive measure against the development of severe forms of COVID-19 not only in patients with asthma.: Methods: In 654 Czech and Slovak patients with asthma who developed COVID-19, ...

Abstract	Background: Inhaled corticosteroids have been widely reported as a preventive measure against the development of severe forms of COVID-19 not only in patients with asthma. Methods: In 654 Czech and Slovak patients with asthma who developed COVID-19, we investigated whether the correct use of inhaler containing corticosteroids was associated with a less severe course of COVID-19 and whether this had an impact on the need for hospitalisation, measurable lung functions and quality of life (QoL). Results: Of the studied cohort 51.4% had moderate persistent, 29.9% mild persistent and 7.2% severe persistent asthma. We found a significant adverse effect of poor inhaler adherence on COVID-19 severity (p=0.049). We also observed a lower hospitalisation rate in patients adequately taking the inhaler with OR of 0.83. Vital capacity and forced expiratory lung volume deterioration caused by COVID-19 were significantly reversed, by approximately twofold to threefold, in individuals who inhaled correctly. Conclusion: Higher quality of inhalation technique of corticosteroids measured by adherence to an inhaled medication application technique (A-AppIT) score had a significant positive effect on reversal of the vital capacity and forced expiratory lung volume in 1 s worsening (p=0.027 and p<0.0001, respectively) due to COVID-19. Scoring higher in the A-AppIT was also associated with significantly improved QoL. All measured variables concordantly and without exception showed a positive improvement in response to better adherence. We suggest that corticosteroids provide protection against the worsening of lungs in patients with COVID-19 and that correct and easily assessable adherence to corticosteroids with appropriate inhalation technique play an important role in preventing severe form of COVID-19.
MeSH term(s)	Humans ; Quality of Life ; COVID-19 ; Asthma/drug therapy ; Adrenal Cortex Hormones ; Forced Expiratory Volume
Chemical Substances	Adrenal Cortex Hormones
Language	English
Publishing date	2024-01-06
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2736454-9
ISSN	2052-4439 ; 2052-4439
ISSN (online)	2052-4439
ISSN	2052-4439
DOI	10.1136/bmjresp-2023-001874
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment.

Novosad, Jakub / Krčmová, Irena / Souček, Ondřej / Drahošová, Marcela / Sedlák, Vratislav / Kulířová, Martina / Králíčková, Pavlína

International journal of molecular sciences

2023 Volume 24, Issue 6

Abstract: The existence of eosinophils was documented histopathologically in the first half of the 19th century. However, the term "eosinophils" was first used by Paul Ehrlich in 1878. Since their discovery and description, their existence has been associated with ...

Abstract	The existence of eosinophils was documented histopathologically in the first half of the 19th century. However, the term "eosinophils" was first used by Paul Ehrlich in 1878. Since their discovery and description, their existence has been associated with asthma, allergies, and antihelminthic immunity. Eosinophils may also be responsible for various possible tissue pathologies in many eosinophil-associated diseases. Since the beginning of the 21st century, the understanding of the nature of this cell population has undergone a fundamental reassessment, and in 2010, J. J. Lee proposed the concept of "LIAR" (Local Immunity And/or Remodeling/Repair), underlining the extensive immunoregulatory functions of eosinophils in the context of health and disease. It soon became apparent that mature eosinophils (in line with previous morphological studies) are not structurally, functionally, or immunologically homogeneous cell populations. On the contrary, these cells form subtypes characterized by their further development, immunophenotype, sensitivity to growth factors, localization, role and fate in tissues, and contribution to the pathogenesis of various diseases, including asthma. The eosinophil subsets were recently characterized as resident (rEos) and inflammatory (iEos) eosinophils. During the last 20 years, the biological therapy of eosinophil diseases, including asthma, has been significantly revolutionized. Treatment management has been improved through the enhancement of treatment effectiveness and a decrease in the adverse events associated with the formerly ultimately used systemic corticosteroids. However, as we observed from real-life data, the global treatment efficacy is still far from optimal. A fundamental condition, "sine qua non", for correct treatment management is a thorough evaluation of the inflammatory phenotype of the disease. We believe that a better understanding of eosinophils would lead to more precise diagnostics and classification of asthma subtypes, which could further improve treatment outcomes. The currently validated asthma biomarkers (eosinophil count, production of NO in exhaled breath, and IgE synthesis) are insufficient to unveil super-responders among all severe asthma patients and thus give only a blurred picture of the adepts for treatment. We propose an emerging approach consisting of a more precise characterization of pathogenic eosinophils in terms of the definition of their functional status or subset affiliation by flow cytometry. We believe that the effort to find new eosinophil-associated biomarkers and their rational use in treatment algorithms may ameliorate the response rate to biological therapy in patients with severe asthma.
MeSH term(s)	Humans ; Eosinophils/metabolism ; Asthma/drug therapy ; Hypersensitivity/metabolism ; Leukocyte Count ; Biomarkers/metabolism
Chemical Substances	Biomarkers
Language	English
Publishing date	2023-03-16
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms24065716
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Ultrasonografické vyšetření hrudníku v rukou lékaře klinika.

Sedlák, Vratislav / Koblížek, Vladimír / Šimek, Rastislav

Vnitrni lekarstvi

Winter 2018 Volume 63, Issue 11, Page(s) 900–907

Abstract: Implementation of ultrasound into clinical medicine is current trend in many subspecialties of internal medicine. Remarkable development and use of this technology is currently present in intensive care and respiratory medicine. This review summarizes ... ...

Title translation	Ultrasound examination of the chest in the hands of the clinical physician.
Abstract	Implementation of ultrasound into clinical medicine is current trend in many subspecialties of internal medicine. Remarkable development and use of this technology is currently present in intensive care and respiratory medicine. This review summarizes current knowledge and nomenclature of artefacts and findings in clinical chest ultrasound. It describes ultrasound-based approach in a differential diagnostic algorithm of acute severe dyspnoea. Chest ultrasound should be a standard knowledge of chest physician.Key words: clinical chest ultrasound - chest drainage - pleural fluid - pneumothorax - thoracocentesis.
MeSH term(s)	Algorithms ; Diagnosis, Computer-Assisted/methods ; Dyspnea/diagnosis ; Dyspnea/etiology ; Humans ; Pneumothorax/diagnosis ; Pulmonary Medicine/methods ; Thorax/diagnostic imaging ; Ultrasonography/methods
Language	Czech
Publishing date	Winter 2018
Publishing country	Czech Republic
Document type	Journal Article
ZDB-ID	138213-5
ISSN	1801-7592 ; 0042-773X
ISSN (online)	1801-7592
ISSN	0042-773X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 327: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 526: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: What bothers severe asthma patients most? A paired patient-clinician study across seven European countries.

ERJ open research

2023 Volume 9, Issue 3

Abstract: Introduction: Severe asthma is a complex, multidimensional disease. Optimal treatment, adherence and outcomes require shared decision-making, rooted in mutual understanding between patient and clinician. This study used a novel, patient-centred approach ...

Abstract	Introduction: Severe asthma is a complex, multidimensional disease. Optimal treatment, adherence and outcomes require shared decision-making, rooted in mutual understanding between patient and clinician. This study used a novel, patient-centred approach to examine the most bothersome aspects of severe asthma to patients, as seen from both perspectives in asthma registries. Methods: Across seven countries, 126 patients with severe asthma completed an open-ended survey regarding most the bothersome aspect(s) of their asthma. Patients' responses were linked with their treating clinician who also completed a free-text survey about each patient's most bothersome aspect(s). Responses were coded using content analysis, and patient and clinician responses were compared. Finally, asthma registries that are part of the SHARP (Severe Heterogeneous Asthma Research collaboration, Patient-centred) Clinical Research Collaboration were examined to see the extent to which they reflected the most bothersome aspects reported by patients. Results: 88 codes and 10 themes were identified. Clinicians were more focused on direct physical symptoms and were less focused on "holistic" aspects such as the effort required to self-manage the disease. Clinicians accurately identified a most bothersome symptom for 29% of patients. Agreement was particularly low with younger patients and those using oral corticosteroids infrequently. In asthma registries, patient aspects were predominantly represented in questionnaires. Conclusions: Results demonstrated different perspectives and priorities between patients and clinicians, with clinicians more focused on physical aspects. These differences must be considered when treating individual patients, and within multidisciplinary treatment teams. The use of questionnaires that include multifaceted aspects of disease may result in improved asthma research.
Language	English
Publishing date	2023-05-30
Publishing country	England
Document type	Journal Article
ZDB-ID	2827830-6
ISSN	2312-0541
ISSN	2312-0541
DOI	10.1183/23120541.00717-2022
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Assessment of regional ventilation with the electrical impedance tomography in a patient after asphyxial cardiac arrest.

Dostal, Pavel / Truhlar, Anatolij / Polak, Josef / Sedlak, Vratislav / Turek, Zdenek

Resuscitation

2014 Volume 85, Issue 8, Page(s) e115–7

MeSH term(s)	Dyspnea/diagnosis ; Dyspnea/etiology ; Dyspnea/therapy ; Electric Impedance ; Heart Arrest/complications ; Heart Arrest/therapy ; Humans ; Male ; Middle Aged ; Respiration, Artificial/methods ; Resuscitation ; Tomography/methods
Language	English
Publishing date	2014-08
Publishing country	Ireland
Document type	Case Reports ; Letter
ZDB-ID	189901-6
ISSN	1873-1570 ; 0300-9572
ISSN (online)	1873-1570
ISSN	0300-9572
DOI	10.1016/j.resuscitation.2014.04.028
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1048: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study.

Frix, Anne-Noelle / Heaney, Liam G / Dahlén, Barbro / Mihaltan, Florin / Sergejeva, Svetlana / Popović-Grle, Sanja / Sedlak, Vratislav / Lehtimäki, Lauri / Bourdin, Arnaud / Korn, Stephanie / Zervas, Eleftherios / Csoma, Zsuzsanna / Lúðvíksdóttir, Dora / Butler, Marcus / Canonica, Giorgio Walter / Grisle, Ineta / Bieksiene, Kristina / Ten Brinke, Anneke / Kuna, Piotr /

Chaves Loureiro, Claudia / Nenasheva, Natalia M / Lazic, Zorica / Škrgat, Sabina / Ramos-Barbon, David / Leuppi, Joerg / Gemicioglu, Bilun / Bossios, Apostolos / Porsbjerg, Celeste M / Bel, Elisabeth H / Djukanovic, Ratko / Louis, Renaud

ERJ open research

2022 Volume 8, Issue 4

Abstract: Introduction: Treatment with biologics for severe asthma is informed by international and national guidelines and defined by national regulating bodies, but how these drugs are used in real-life is unknown.: Materials and methods: The European ... ...

Abstract	Introduction: Treatment with biologics for severe asthma is informed by international and national guidelines and defined by national regulating bodies, but how these drugs are used in real-life is unknown. Materials and methods: The European Respiratory Society (ERS) SHARP Clinical Research Collaboration conducted a three-step survey collecting information on asthma biologics use in Europe. Five geographically distant countries defined the survey questions, focusing on seven end-points: biologics availability and financial issues, prescription and administration modalities, inclusion criteria, continuation criteria, switching biologics, combining biologics and evaluation of corticosteroid toxicity. The survey was then sent to SHARP National Leads of 28 European countries. Finally, selected questions were submitted to a broad group of 263 asthma experts identified by national societies. Results: Availability of biologics varied between countries, with 17 out of 28 countries having all five existing biologics. Authorised prescribers (pulmonologists and other specialists) also differed. In-hospital administration was the preferred deliverance modality. While exacerbation rate was used as an inclusion criterion in all countries, forced expiratory volume in 1 s was used in 46%. Blood eosinophils were an inclusion criterion in all countries for interleukin-5 (IL-5)-targeted and IL-4/IL-13-targeted biologics, with varying thresholds. There were no formally established criteria for continuing biologics. Reduction in exacerbations represented the most important benchmark, followed by improvement in asthma control and quality of life. Only 73% (191 out of 263) of surveyed clinicians assessed their patients for corticosteroid-induced toxicity. Conclusion: Our study reveals important heterogeneity in the use of asthma biologics across Europe. To what extent this impacts on clinical outcomes relevant to patients and healthcare services needs further investigation.
Language	English
Publishing date	2022-10-24
Publishing country	England
Document type	Journal Article
ZDB-ID	2827830-6
ISSN	2312-0541
ISSN	2312-0541
DOI	10.1183/23120541.00273-2022
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Immunomagnetic molecular probe with UHPLC-MS/MS: a promising way for reliable bronchial asthma diagnostics based on quantification of cysteinyl leukotrienes.

Syslová, Kamila / Böhmová, Adéla / Demirbağ, Elvan / Šimková, Kateřina / Kuzma, Marek / Pelclová, Daniela / Sedlák, Vratislav / Čáp, Petr / Martásek, Pavel / Kačer, Petr

Journal of pharmaceutical and biomedical analysis

2013 Volume 81-82, Page(s) 108–117

Abstract: A sensitive and precise method for simultaneous quantification of cysteinyl leukotrienes (=cys LTs) - leukotriene C4 (=LTC4), leukotriene D4 (=LTD4) and leukotriene E4 (=LTE4) - essential biomarkers of bronchial asthma present in exhaled breath ... ...

Abstract	A sensitive and precise method for simultaneous quantification of cysteinyl leukotrienes (=cys LTs) - leukotriene C4 (=LTC4), leukotriene D4 (=LTD4) and leukotriene E4 (=LTE4) - essential biomarkers of bronchial asthma present in exhaled breath condensate (=EBC) was developed. An immunomagnetic molecular probe was prepared by anchoring cysteinyl leukotrienes antibody on the surface of functionalized monodispersed magnetic particles and used to selectively isolate cys LTs from biological matrices - EBC, plasma and urine. Immobilization and the immunoaffinity capture procedures were optimized to maximize the amount of separated cys LTs, which were detected "off-beads" after acidic elution by UHPLC-ESI-MS/MS operated in a multiple reaction monitoring mode. The developed method was characterized with high precision ≤13.6% (intra-day precision determined as RSD) and ≤14.5% (inter-day precision determined as RSD), acceptable accuracy ≤18.5% (determined as RE), and high recovery of immunoseparation (≥93.1%) in aforementioned biological matrices. The applicability of the method was demonstrated on EBC, plasma and urine clinical samples of patients with various subtypes of bronchial asthma (occupational, steroid-resistant, moderate with and without corticosteroids therapy) and healthy subjects where reasonable differences in cys LTs concentration levels were found. Combining extremely selective immunomagnetic separation with highly sensitive and precise detection step, the developed method was used to aid diagnosis, predict the most effective therapy, and monitor the response to treatment. The detection of elevated inflammatory mediators (cys LTs) in EBC of subjects with relatively asymptomatic asthma and normal pulmonary function tests could offer a novel way for monitoring the lung inflammation and perhaps initiating treatment in an earlier stage.
MeSH term(s)	Asthma/diagnosis ; Asthma/drug therapy ; Asthma/physiopathology ; Breath Tests ; Case-Control Studies ; Chromatography, High Pressure Liquid/methods ; Glucocorticoids/therapeutic use ; Humans ; Immunomagnetic Separation/methods ; Leukotriene C4/analysis ; Leukotriene D4/analysis ; Leukotriene E4/analysis ; Middle Aged ; Reproducibility of Results ; Sensitivity and Specificity ; Spectrometry, Mass, Electrospray Ionization/methods ; Tandem Mass Spectrometry/methods
Chemical Substances	Glucocorticoids ; Leukotriene C4 (2CU6TT9V48) ; Leukotriene D4 (73836-78-9) ; Leukotriene E4 (75715-89-8)
Language	English
Publishing date	2013-07
Publishing country	England
Document type	Controlled Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't ; Validation Studies
ZDB-ID	604917-5
ISSN	1873-264X ; 0731-7085
ISSN (online)	1873-264X
ISSN	0731-7085
DOI	10.1016/j.jpba.2013.03.026
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1850: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immunomagnetic molecular probe with UHPLC–MS/MS: A promising way for reliable bronchial asthma diagnostics based on quantification of cysteinyl leukotrienes

Syslová, Kamila / Böhmová, Adéla / Demirbağ, Elvan / Šimková, Kateřina / Kuzma, Marek / Pelclová, Daniela / Sedlák, Vratislav / Čáp, Petr / Martásek, Pavel / Kačer, Petr

Journal of pharmaceutical and biomedical analysis. 2013 , v. 81-82

2013

Abstract: A sensitive and precise method for simultaneous quantification of cysteinyl leukotrienes (=cys LTs) – leukotriene C₄ (=LTC₄), leukotriene D₄ (=LTD₄) and leukotriene E₄ (=LTE₄) – essential biomarkers of bronchial asthma present in exhaled breath ... ...

Abstract	A sensitive and precise method for simultaneous quantification of cysteinyl leukotrienes (=cys LTs) – leukotriene C₄ (=LTC₄), leukotriene D₄ (=LTD₄) and leukotriene E₄ (=LTE₄) – essential biomarkers of bronchial asthma present in exhaled breath condensate (=EBC) was developed. An immunomagnetic molecular probe was prepared by anchoring cysteinyl leukotrienes antibody on the surface of functionalized monodispersed magnetic particles and used to selectively isolate cys LTs from biological matrices – EBC, plasma and urine. Immobilization and the immunoaffinity capture procedures were optimized to maximize the amount of separated cys LTs, which were detected “off-beads” after acidic elution by UHPLC–ESI-MS/MS operated in a multiple reaction monitoring mode. The developed method was characterized with high precision ≤13.6% (intra-day precision determined as RSD) and ≤14.5% (inter-day precision determined as RSD), acceptable accuracy ≤18.5% (determined as RE), and high recovery of immunoseparation (≥93.1%) in aforementioned biological matrices. The applicability of the method was demonstrated on EBC, plasma and urine clinical samples of patients with various subtypes of bronchial asthma (occupational, steroid-resistant, moderate with and without corticosteroids therapy) and healthy subjects where reasonable differences in cys LTs concentration levels were found. Combining extremely selective immunomagnetic separation with highly sensitive and precise detection step, the developed method was used to aid diagnosis, predict the most effective therapy, and monitor the response to treatment. The detection of elevated inflammatory mediators (cys LTs) in EBC of subjects with relatively asymptomatic asthma and normal pulmonary function tests could offer a novel way for monitoring the lung inflammation and perhaps initiating treatment in an earlier stage.
Keywords	adrenal cortex hormones ; asthma ; biomarkers ; diagnostic techniques ; immunomagnetic separation ; leukotrienes ; lung function ; monitoring ; patients ; pneumonia ; therapeutics ; urine
Language	English
Dates of publication	2013-07
Size	p. 108-117.
Publishing place	Elsevier B.V.
Document type	Article
ZDB-ID	604917-5
ISSN	0731-7085
ISSN	0731-7085
DOI	10.1016/j.jpba.2013.03.026
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 1850: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care.

Koblizek, Vladimir / Chlumsky, Jan / Zindr, Vladimir / Neumannova, Katerina / Zatloukal, Jakub / Zak, Jaroslav / Sedlak, Vratislav / Kocianova, Jana / Zatloukal, Jaromir / Hejduk, Karel / Pracharova, Sarka

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia

2013 Volume 157, Issue 2, Page(s) 189–201

Abstract: Background: COPD is a global concern. Currently, several sets of guidelines, statements and strategies to managing COPD exist around the world.: Methods: The Czech Pneumological and Phthisiological Society (CPPS) has commissioned an Expert group to ... ...

Abstract	Background: COPD is a global concern. Currently, several sets of guidelines, statements and strategies to managing COPD exist around the world. Methods: The Czech Pneumological and Phthisiological Society (CPPS) has commissioned an Expert group to draft recommended guidelines for the management of stable COPD. Subsequent revisions were further discussed at the National Consensus Conference (NCC). Reviewers' comments contributed to the establishment of the document's final version. Diagnosis: The hallmark of the novel approach to COPD is the integrated evaluation of the patient's lung functions, symptoms, exacerbations and identifications of clinical phenotype(s). The CPPS defines 6 clinically relevant phenotypes: frequent exacerbator, COPD-asthma overlap, COPD-bronchiectasis overlap, emphysematic phenotype, bronchitic phenotype and pulmonary cachexia phenotype. Treatment: Treatment recommendations can be divided into four steps. 1(st) step = Risk exposure elimination: reduction of smoking and environmental tobacco smoke (ETS), decrease of home and occupational exposure risks. 2(nd) step = Standard treatment: inhaled bronchodilators, regular physical activity, pulmonary rehabilitation, education, inhalation training, comorbidity treatment, vaccination. 3(rd) step = Phenotype-specific therapy: PDE4i, ICS+LABA, LVRS, BVR, AAT augmentation, physiotherapy, mucolytic, ABT. 4(th) step = Care for respiratory insufficiency and terminal COPD: LTOT, lung transplantation, high intensity-NIV and palliative care. Conclusion: Optimal treatment of COPD patients requires an individualised, multidisciplinary approach to the patient's symptoms, clinical phenotypes, needs and wishes. The new Czech COPD guideline reflects and covers these requirements.
MeSH term(s)	Consensus ; Czech Republic ; Humans ; Patient Care Planning ; Patient-Centered Care ; Pulmonary Disease, Chronic Obstructive/classification ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/therapy ; Pulmonary Medicine ; Societies, Medical
Language	English
Publishing date	2013-06
Publishing country	Czech Republic
Document type	Journal Article ; Practice Guideline
ZDB-ID	17196-7
ISSN	1804-7521 ; 1213-8118 ; 0231-5599 ; 0862-481X
ISSN (online)	1804-7521
ISSN	1213-8118 ; 0231-5599 ; 0862-481X
DOI	10.5507/bp.2013.039
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6675: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito